In March 2026, clinics in Kenya experienced a sudden disruption in donor funding, leading to stalled supply chains and unanswered questions from programme coordinators. This incident highlighted the reliance of the country's public health infrastructure on external financial support, raising concerns about the implications of the Kenya-US health data deal, according to TechTrends KE.

A report from Soko Directory highlights that Kenyan families often prioritize immediate medical treatment over purchasing health insurance, leading to significant expenditures on healthcare. The article suggests that in medical emergencies, the first response is typically a phone call rather than considering financial investments. This behavior reflects a broader hesitation among Kenyans to invest in insurance despite the high costs associated with medical treatment.

A new report suggests that governments and global health donors should explore the potential of private pharmacies as a means to enhance access to care for HIV, tuberculosis, and malaria. This recommendation comes in light of decreasing funding for public health systems globally. The report is titled "Private Pharmacies as a Delivery Channel for HIV, TB, and Malaria Care."

The National Assembly Health Committee has highlighted issues within the Social Health Authority (SHA), noting that while 30 million Kenyans are registered, only 4 to 5 million have paid the necessary premiums to qualify for inpatient hospital services. This concern was raised during a recent meeting, indicating significant gaps in healthcare access related to the SHA.

The article discusses the impact of a single hospital bill on financial stability, highlighting the case of Mary and her husband Daniel. It illustrates how unexpected medical expenses can undermine years of financial progress, particularly in the context of Jubilee Health Insurance. The narrative emphasizes the broader implications of healthcare costs on individuals and families.

The Ministry of Health in Uganda has announced the arrival of an additional 19,200 doses of lenacapavir, a long-acting injectable drug for HIV prevention, due to increasing demand. This shipment is expected next month and will primarily be used for administering second injections to individuals already receiving the treatment.